Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and [18F]deuteroaltanserin
暂无分享,去创建一个
Robert B. Innis | John Seibyl | Sami S. Zoghbi | Jair C. Soares | Pradeep Garg | Ronald M. Baldwin | Masahiro Fujita | Robert Soufer | J. Seibyl | J. Soares | J. Staley | S. Zoghbi | R. Innis | M. Fujita | R. Baldwin | P. Tan | R. Soufer | P. Garg | C. V. Dyck | Julie K. Staley | Christopher H. van Dyck | Ping-Zhong Tan | Xing Fu | Lou Amici | L. Amici | Xing Fu
[1] P. Maquet,et al. Serotonin 5HT2 Receptor Imaging in the Human Brain Using Positron Emission Tomography and a New Radioligand, [18F]Altanserin: Results in Young Normal Controls , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[2] S. Kapur,et al. Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects. , 1999, The American journal of psychiatry.
[3] G. Aghajanian,et al. The role of serotonin in the pathophysiology and treatment of schizophrenia. , 1997, The Journal of neuropsychiatry and clinical neurosciences.
[4] A. Hirano,et al. AN ATLAS OF THE HUMAN BRAIN FOR COMPUTERIZED TOMOGRAPHY. , 1978 .
[5] J. Seibyl,et al. Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] Vincent J. Cunningham,et al. Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.
[7] C Crouzel,et al. Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone. , 1993, Brain : a journal of neurology.
[8] Donald Sashin,et al. Test–retest variability of serotonin 5‐HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain , 1998, Synapse.
[9] C Crouzel,et al. [18F]setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. , 1988, European journal of pharmacology.
[10] J. Soares,et al. Neurochemical brain imaging investigations of schizophrenia , 1999, Biological Psychiatry.
[11] D. Charney,et al. PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] C. Lemaire,et al. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] S. Kapur,et al. Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. , 1999, The American journal of psychiatry.
[14] S Adler,et al. Design and performance of POSICAM 6.5 BGO positron camera. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] J. Mazziotta,et al. MRI‐PET Registration with Automated Algorithm , 1993, Journal of computer assisted tomography.
[16] J. Baron,et al. Estimation of neocortical serotonin-2 receptor binding potential by single-dose fluorine-18-setoperone kinetic PET data analysis. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] R. Kirk. Experimental Design: Procedures for the Behavioral Sciences , 1970 .
[18] D. Charney,et al. Rapid synthesis of F-18 and H-2 dual-labeled altanserin, a metabolically resistant PET ligand for 5-HT2a receptors , 1999 .
[19] C. Halldin,et al. [11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography. , 1996, Life sciences.
[20] Mann Jj. The role of in vivo neurotransmitter system imaging studies in understanding major depression. , 1998 .
[21] C. Halldin,et al. PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] B. Mazoyer,et al. The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine , 1999, Biological Psychiatry.
[23] M. Mintun,et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.
[24] J. Seibyl,et al. Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm. , 2000, Nuclear medicine and biology.
[25] D. Charney,et al. Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent. , 1999, Nuclear medicine and biology.
[26] H. Mayberg,et al. PET imaging of cortical S2 serotonin receptors after stroke: lateralized changes and relationship to depression. , 1988, The American journal of psychiatry.
[27] S. Zoghbi,et al. Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. , 1994, Journal of pharmaceutical sciences.
[28] Gerhard Gründer,et al. Time Course of 5-HT2A Receptor Occupancy in the Human Brain after a Single Oral Dose of the Putative Antipsychotic Drug MDL 100,907 Measured by Positron Emission Tomography , 1997, Neuropsychopharmacology.
[29] D. Charney,et al. A complete remote-control system for reliable preparation of [18F]altanserin. , 1999, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.